News
-
-
2026-09-16
GenEditBio Receives FDA Fast Track Designation for Its Lead In Vivo Genome-Editing Program GEB-101 for the Treatment of TGFBI-Related Corneal Dystrophies
GenEditBio receives U.S. FDA Fast Track Designation for its lead in vivo genome-editing program GEB-101 for the treatment of TGFBI-related corneal dystrophies
more >
-
2026-07-10
今日一小步，明日大希望！
A small step today, a giant leap of hope for tomorrow!
more >
-
2026-07-02
引正基因首个体内基因组编辑药物GEB-101获得NMPA药物临床试验批准 用于治疗TGFBI相关的角膜营养不良
GenEditBio receives NMPA clearance of IND application for Its lead in vivo genome-editing program GEB-101 for TGFBI-related corneal dystrophies
more >
-
-
-
Featured on the Cover of Nature Biomedical Engineering — February 2026
Related Press Release (13 August 2025):
넳 넲
Copyright © 2025 GenEditBio
Provide affordable precision DNA surgery for genetic diseases with unmet needs
Business Contact bd@geneditbio.com
Media Contact geb.media@geneditbio.com
HONG KONG Unit 101-102, Building 6W, 6 Science Park West Avenue, Hong Kong hkoffice@geneditbio.com
BEIJING 4/F, Building 29, Yard 18, Kechuang 13th St, VPark, Beijing
